Please use this identifier to cite or link to this item: https://doi.org/10.1111/j.1471-0528.2006.01057.x
DC FieldValue
dc.titleThe advent of international 'mail-order' egg donation
dc.contributor.authorHeng, B.C.
dc.date.accessioned2013-10-16T07:17:25Z
dc.date.available2013-10-16T07:17:25Z
dc.date.issued2006
dc.identifier.citationHeng, B.C. (2006). The advent of international 'mail-order' egg donation. BJOG: An International Journal of Obstetrics and Gynaecology 113 (11) : 1225-1227. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1471-0528.2006.01057.x
dc.identifier.issn14700328
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/47120
dc.description.abstractThe rising demand and increasing scarcity of donor oocytes in developed countries have led to some fertility clinics sourcing oocyte donors from abroad, particularly from poorer countries, in what is referred to as 'transnational' or 'international' oocyte donation. In a further new 'twist' to this scheme, frozen sperm of the recipient's male partner is exported abroad through courier mail and is used to fertilise donor oocytes in a foreign clinic to produce embryos, which are then cryopreserved and imported back by mail for transfer to the woman. There are numerous ethical concerns with regards to such means of procuring donor oocytes. First, there is an issue of exploiting economically underprivileged women in poorer countries and disproportionate gains on the part of medical doctors and fertility clinics. Second, there is a question of abdication of responsibility for the donor's welfare on the part of the fertility doctor who takes charge of the recipient's treatment abroad if oocyte donors were to develop severe ovarian hyperstimulation syndrome. Third, the issue of responsibility and accountability becomes even more contentious if congenital defects were to appear in offsprings born from transnational oocyte donation or in the case of transmission of communicable diseases such as hepatitis B, syphilis and AIDS to the recipient. Last, cost savings from the lower prescription price of fertility drugs in economically less-developed countries may not be passed down to the oocyte recipient but instead be exploited to boost the already substantial profit margin of fertility clinics and doctors. © RCOG 2006 BJOG An International Journal of Obstetrics and Gynaecology.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1111/j.1471-0528.2006.01057.x
dc.sourceScopus
dc.subjectCommercialisation
dc.subjectDonation
dc.subjectEthics
dc.subjectMail order
dc.subjectOocyte
dc.typeReview
dc.contributor.departmentDEAN'S OFFICE (DENTISTRY)
dc.description.doi10.1111/j.1471-0528.2006.01057.x
dc.description.sourcetitleBJOG: An International Journal of Obstetrics and Gynaecology
dc.description.volume113
dc.description.issue11
dc.description.page1225-1227
dc.description.codenBIOGF
dc.identifier.isiut000241234600001
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.